0
Tobacco Cessation |

Differences in Results of Two Follow-up Periods in a Tobacco Cessation Unit in Albacete University Hospital

Francisco Javier Callejas Gonzalez, PhD; Abel Martinez Garcia, MD; Marta Genoves Crespo, MD; Juan Pastrana Calderón, MD; Angel Molina Cano, MD; Ana Isabel Tornero Molina, MD; Mariela Plenc Ziegler, MD; Javier Cruz Ruiz, MD; Sergio García Castillo, MD; Raúl Godoy Mayoral, MD
Author and Funding Information

Complejo Hospitalario Universitario de Albacete, Albacete, Spain


Chest. 2014;145(3_MeetingAbstracts):611A. doi:10.1378/chest.1835573
Text Size: A A A
Published online

Abstract

SESSION TITLE: Tobacco Cessation and Prevention Posters

SESSION TYPE: Poster Presentations

PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM

PURPOSE: Review and compare the results analyzed in a Tobacco Cessation Unit during 2004 and 2008.

METHODS: Retrospective descriptive and comparative analysis of the results obtained from patients who were attended in a Tobacco Cessation Unit from January 1st to December 31 in 2004 and another treated from January 1st to December 31 in 2008 and the subsequent follow-up to complete one year.

RESULTS: 2004: 318 (60,4% males) , mean age 45,9 years and mean cigarettes/day, 26. Respiratory comorbidity: 24,2% COPD, 9,7% asthma and 8,2% OSAHS. Psychiatric comorbidity, 26,1%. Moderate nicotine dependence (mean Fagerström 5,96) and high motivation (mean Richmond 8,97). 8,8% without treatment, 71,7% NRT and 19,5% bupropion. Overall the 318 patients, successful treatment in 68 (21,4%), 41 men and 27 women; this percentage rises up to 31,2% if we do not consider those who did not attend the second consultation. 2008: 268 (56,3 % males), 46 years and 27,1 cigarettes/day. Respiratory comorbidity: 15,7% COPD, 9% asthma and 10,8% OSAHS. Psychiatric comorbidity, 32.46%. Moderate-severe nicotine dependence (mean Fagerström 6,22) and high motivation (mean Richmond 8,18). 44,4% without treatment, 22,8% NRT, 6,3% bupropion and 26,5% varenicline. Overall the 268 patients, successful treatment in 45 (16,8%), 29 men and 16 women; this percentage rises up to 29,6% if we do not consider those who did not attend the second consultation.

CONCLUSIONS: 1. Slighty higher men frecuency, similar mean age and slighty lower mean cigarettes/day in 2004. 2. Higher respiratory and lower psychiatric comorbidity in 2004. 3. Lower nicotine dependence and higher motivation in 2004. 4. No use VRN in 2004. 5. Treatment success were similar in both years (31,2 vs. 29,6%).

CLINICAL IMPLICATIONS: Smoking cessation treatment is effective but it requires patients commitment. Probably there is no difference in these years because in 2008 patients had lower motivation, higher psychiatric comorbidity and poor use of medication. There is an overall use of medication success of 17-20 %, rising up to 29-31% if we exclude those who did not attend the second consultation.

DISCLOSURE: The following authors have nothing to disclose: Francisco Javier Callejas Gonzalez, Abel Martinez Garcia, Marta Genoves Crespo, Juan Pastrana Calderón, Angel Molina Cano, Ana Isabel Tornero Molina, Mariela Plenc Ziegler, Javier Cruz Ruiz, Sergio García Castillo, Raúl Godoy Mayoral

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543